Impact of diabetes on absenteeism, disability, and medical costs in the U.S. workforce: differences by disease progression and industry.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42551016.
- Also identified by DOI 10.1097/JOM.0000000000003846.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To estimate the impact of type 2 diabetes on absenteeism, disability, productivity loss, and healthcare costs, stratified by diabetes progression and industry. Using 2016-2019 Merative™ MarketScan® databases, we conducted a retrospective analysis of full-time employees: newly diagnosed type 2 diabetes (T2D-New), established type 2 diabetes (T2D-Estab), or without diabetes (T2D-Neg). Per-capita annual productivity loss and healthcare costs were estimated using two-part models adjusted for demographics, industry, and comorbidity. Among 3.8 million U.S. employees, T2D-New and T2D-Estab experienced significantly higher annual productivity loss (+$373.2 and +$140.1) and healthcare costs (+$2160.9 and +$1957.7) compared with T2D-Neg (p<0.001). Total annual costs reached approximately $8,000 per employee with T2D. Patterns were consistent across industries. These findings highlight the workforce impact of diabetes and support the benefit of occupational health and wellness interventions.